Humacyte, Inc.HUMAEarnings & Financial Report
Humacyte, Inc. is a clinical-stage biotechnology firm focused on developing and commercializing universally implantable off-the-shelf bioengineered human tissues and therapeutic products. Its core offerings target unmet needs in vascular care, trauma treatment and regenerative medicine, serving patients and healthcare partners worldwide.
HUMA Q4 FY2025 Key Financial Metrics
Revenue
$467.0K
Gross Profit
$-8.6M
Operating Profit
$-30.8M
Net Profit
N/A
Gross Margin
-1844.8%
Operating Margin
-6603.0%
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.19
Humacyte, Inc. Q4 FY2025 Financial Summary
Humacyte, Inc. reported revenue of $467.0K for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $9.1M, operating expenses totaled $22.2M.
Key Financial Metrics
| Total Revenue | $467.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | -1844.8% |
| Operating Margin | -6603.0% |
| Report Period | Q4 FY2025 |
Humacyte, Inc. Annual Revenue by Year
Humacyte, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.0M).
Humacyte, Inc. Quarterly Revenue & Net Profit History
Humacyte, Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $467.0K | — | N/A | N/A |
| Q3 FY2025 | $753.0K | — | $-17.5M | -2325.4% |
| Q2 FY2025 | $301.0K | — | $-37.7M | -12511.0% |
| Q1 FY2025 | $517.0K | — | $39.1M | 7570.4% |
| Q3 FY2024 | $0 | — | $-39.2M | N/A |
| Q2 FY2024 | $0 | — | $-56.7M | N/A |
| Q1 FY2024 | $0 | — | $-31.9M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $517000 | $301000 | $753000 | $467000 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $161.5M | $138.3M | $114.8M | $162.6M | $138.8M | $91.5M | $116.4M |
| Liabilities | $135.3M | $166.6M | $178.5M | $126.5M | $134.7M | $96.3M | $113.3M |
| Equity | $26.2M | $-28.3M | $-63.7M | $36.0M | $4.1M | $-4.8M | $3.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-27.3M | $-21.3M | $-22.9M | $-28.6M | $-26.4M | $-23.9M | $-26.1M |